However, also comparing the expected outcomes of a third stage of SCLC, we have achieved a great result (median OS of 15-20 months with a two-year survival rate of 20-40%) [19]. Liu et al. [3] published updated OS data of Impower133 and they ran an exploratory analysis of efficacy based on PD-L1 expression levels. This evidence concerns the gene CD274 and small cell lung carcinoma.